🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  2. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALEN® Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  4. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  5. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial

  6. APD334

    Arena Pharmaceutical Enterprises Limited

    Pyoderma Gangrenosum

    phase 2 small molecule terminated

    1 trial

  7. APG777

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    3 trials

  8. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  9. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  10. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  11. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  12. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  13. APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  14. ARC-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    2 trials

  15. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial

  16. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials

  17. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  18. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  19. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  20. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  21. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  22. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 2 small molecule completed

    1 trial

  23. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  24. ARO-DIMERPA

    Arrowhead Pharmaceuticals Ireland Limited

    Hyperlipidemia; Mixed

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources